's potential in the market. In summary, the recent earnings call has provided a strong indication of the company's growth and success in the first quarter of 2017. The Hematology and Oncology franchise has shown significant growth and positive performance in key medications such as REVLIMID, POMALYST/IMNOVID, and ABRAXANE. The company has achieved key regulatory and clinical milestones, such as obtaining reimbursement in multiple countries and advancing plans for new drug submissions. The company's pipeline is also making great progress with pivotal plans for multiple assets, showing potential for future growth and success. Additionally, the company's collaborations with other entities are producing exciting data for anticipated FDA submissions. Overall, the company is on track to deliver its 2017 guidance and has a strong outlook for future growth and profitability. Based on the positive performance and future potential indicated in the earnings call, it is recommended to take an 'overweight' investment stance on the company. With the expected FDA approval of POMALYST in combination with daratumumab and the upcoming Phase III trial results for ABRAXANE, there are multiple growth drivers ahead for the company. Therefore, it is a compelling opportunity for investors to consider for potential investment.